Tempus AI has an immunology risk testing product ready for researchers to test out and is working with Cleveland Clinic on better ways to assess how immunotherapy might work on patients. The ...
Ambry Genetics, a subsidiary of Tempus AI, announced completion of 1 million DNA/RNA tests for hereditary cancer and rare ...
Northwestern Medicine and Tempus AI, Inc. (NASDAQ: TEM) are collaborating to expand access to genomic testing for Northwestern Medicine cancer patients. The goal is to provide nearly every patient ...
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the clinical launch of its ...
Ambry Genetics, part of Tempus AI, contributed to research using advanced genetic assays to refine how hereditary cancer ...
Tempus announced this morning it has inked agreements for in-network provider status with Blue Cross Blue Shield health plans in six states, significantly enhancing its relationships with commercial ...
New RNA-based algorithm is now available with the xR assay “This program is truly the intersection of all three of our business units – genomics, AI applications, and data – leveraging our deep ...
CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the national launch of the ...
CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (TEM), a technology company leading the adoption of AI to advance precision medicine, today announced results from a new study demonstrating that its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results